Cytokinetics-Astellas Agree to Develop Muscle Treatments

Cytokinetics Inc. and Astellas Pharma Inc. said they agreed to a deal worth as much as $490 million plus royalties to develop drugs for muscle weakness.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.